Tigecycline

IUPAC Name: N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide
Molecular Formula: C₂₉H₃₉N₅O₈
Molecular Weight: 585.65 g/mol
Classification Code: Anti-Bacterial Agents; Anti-Infective Agents; Antibacterial [bacterial protein synthesis inhibitor]
Product Categories: Antibacterial
XLogP3: -0.2
H-Bond Donor: 7
H-Bond Acceptor: 12
Surface Tension: 80.036 dyne/cm
Density: 1.455 g/cm³
Flash Point: 492.612 °C
Enthalpy of Vaporization: 135.666 kJ/mol
Boiling Point: 890.922 °C at 760 mmHg
Vapour Pressure of Tigecycline (CAS NO.220620-09-7): 0 mmHg at 25 °C

 Tigecycline (CAS NO.220620-09-7) is active against many bacteria including Gram-positive bacteria, Gram-negative bacteria and anaerobes ,it also has activity against methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant strains of Acinetobacter baumannii. It may have no activity against Pseudomonas spp. or Proteus spp. The drug is licenced for the treatment of skin,soft tissue infections ,and intra-abdominal infections.

  Tigecycline (CAS NO.220620-09-7), its Synonyms are 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-((((1,1-dimethylethyl)amino)acetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- ; Tygacil ; (4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide . Tigecycline is bacteriostatic and is a protein synthesis inhibitor by binding to the 30S ribosomal subunit of bacteria and thereby blocking entry of Aminoacyl-tRNA into the A site of the ribosome during prokaryotic translation.